A Feasibility Study of the Millipede Transcatheter Annuloplasty Ring System in Patients With Functional Mitral Regurgitation
← catalyst calendarSponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Device feasibility
Enrollment
4actual
Sites
4
Countries
Australia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-11-13 | actual | When the study began enrolling |
| Primary completion | 2021-12-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2019-11-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Mitral Regurgitation Functional
- Mitral Valve Disease
- Cardiovascular Diseases
Intervention
- Device: Millipede Transcatheter Annuloplasty Ring System (Millipede System)
Primary outcomes
what the primary-completion date above is the date OFPrimary Technical Success Endpoint
measured Index procedure exit from the catheterization laboratory
Primary Safety Endpoint
measured 30 days post index procedure
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed